These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 994219)

  • 1. Antitumor activity of killed Corynebacterium parvum suspensions in a murine mammary adenocarcinoma CaD2) system.
    Purnell DM; Otterstrom JR; Bartlett GL; Kreider JW
    J Natl Cancer Inst; 1976 Jun; 56(6):1171-5. PubMed ID: 994219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG
    Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum.
    Likhite VV
    J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
    Kreider JW; Bartlett GL; Purnell DM; Webb S
    Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of C. parvum on intratumor immunity to the T1699 mammary adenocarcinoma.
    Haskill S; Ritter F; Becker S
    J Immunol; 1980 Jul; 125(1):454-8. PubMed ID: 6247400
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative antitumor effects of Corynebacterium parvum, Bordetella pertussis, Bacillus Calmette-Guérin, and levamisole alone or in combination with cyclophosphamide in the CaD2 murine mammary adenocarcinoma system.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG; Kontra J
    Cancer Res; 1979 Dec; 39(12):4838-42. PubMed ID: 498111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rejection of tumors and metastases in Fischer 344 rats following intratumor administration of killed Corynebacterium parvum.
    Likhite VV
    Int J Cancer; 1974 Nov; 14(5):684-90. PubMed ID: 4459281
    [No Abstract]   [Full Text] [Related]  

  • 8. Lasting rejection of mammary adenocarcinoma cell tumors in DBA-2 mice with intratumor injection of killed Corynebacterium parvum.
    Likhite VV; Halpern BN
    Cancer Res; 1974 Feb; 34(2):341-4. PubMed ID: 4810906
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship between intradermal tumor suppression and tumor immunity.
    Bartlett GL; Kreider JW; Purnell DM
    J Natl Cancer Inst; 1976 Dec; 57(6):1297-303. PubMed ID: 794505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dose and schedule of immune stimulant on efficacy of combination Corynebacterium parvum-cyclophosphamide treatment for a murine mammary adenocarcinoma.
    Purnell DM; Bartlett GL; Kreider JW
    Cancer Res; 1979 Jan; 39(1):1-5. PubMed ID: 761179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of prolonged Corynebacterium parvum and cyclophosphamide administration on the growth of established tumors.
    Fisher B; Wolmark N; Saffer E; Fisher ER
    Cancer; 1975 Jan; 35(1):134-43. PubMed ID: 1109767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cancer using Corynebacterium parvum: similarity of two preparations in four animal tumor models.
    Bartlett GL; Kreider JW; Purnell DM
    Cancer; 1980 Aug; 46(4):685-91. PubMed ID: 7397633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rejection of mammary adenocarcinoma cell tumors in DBA/2 mice immunocompromised by thymectomy and treatment with antithymocyte serum.
    Likhite VV
    J Immunol; 1975 Jun; 114(6):1736-42. PubMed ID: 1092759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Destruction of regional lymph node metastases of rat mammary adenocarcinoma 13762A by treatment with Corynebacterium parvum.
    Kreider JW; Bartlett GL; Purnell DM; Webb S
    Cancer Res; 1978 Dec; 38(12):4522-6. PubMed ID: 719637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antitumor effect of lymphoid cells from Corynebacterium parvum-treated mice: effect of route of C. parvum administration.
    Ghaffar A; Cullen RT
    J Natl Cancer Inst; 1977 Mar; 58(3):717-20. PubMed ID: 300113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of radiation responses of murine tumors by misonidazole (Ro 07-0582), host immune capability, and Corynebacterium parvum.
    Stone HB; Milas L
    J Natl Cancer Inst; 1978 Apr; 60(4):887-93. PubMed ID: 633396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of antitumor activity of Bordetella pertussis in two murine tumor models.
    Purnell DM; Kreider JW; Bartlett GL
    J Natl Cancer Inst; 1975 Jul; 55(1):123-8. PubMed ID: 169359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fc receptor-bearing and phagocytic cells in syngeneic tumours of C. parvum- and carrageenan-treated mice.
    Thomson AW; Cruickshank N; Fowler EF
    Br J Cancer; 1979 May; 39(5):598-602. PubMed ID: 486317
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined radiotherapy and Corynebacterium parvum treatment of rat tumors with different immunogenicity.
    Moroson H; Stowe S; Rotman M; Schechter M
    Int J Radiat Oncol Biol Phys; 1978; 4(7-8):649-55. PubMed ID: 711536
    [No Abstract]   [Full Text] [Related]  

  • 20. Active experimental inhibition of cancer by corynebacterium parvum.
    Wrba H; Dutter A
    Osterr Z Onkol; 1977 Oct; 4(2-3):60-1. PubMed ID: 579449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.